作者
Susanne Saussele, Johan Richter, Joelle Guilhot, Franz X Gruber, Henrik Hjorth-Hansen, Antonio Almeida, Jeroen JWM Janssen, Jiri Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson-Strömberg, Joaquin Martinez-Lopez, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Katerina Machová Poláková, Martin C Müller, Satu Mustjoki, Marc G Berger, Alice Fabarius, Wolf-Karsten Hofmann, Andreas Hochhaus, Markus Pfirrmann, Francois-Xavier Mahon, Gert Ossenkoppele, Maria N Pagoni, Stina Söderlund, Martine Escoffre-Barbe, Gabriel Etienne, Jolanta Dengler, Francoise Huguet, Nikolas von Bubnoff, Hana Klamova, Edgar Faber, Francois Guilhot, Kourosh Lotfi, Delphine Rea, Tim H Brümmendorf, Gorgine E de Greef, Leif Stenke, Franck E Nicolini, Laurence Legros, Andreas Burchert, Jaroslava Voglova, Aude Charbonnier, Emmanuel Gyan, Volker Kunzmann, Peter E Westerweel
发表日期
2018/6/1
期刊
The Lancet Oncology
卷号
19
期号
6
页码范围
747-757
出版商
Elsevier
简介
Background
Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a prerequisite for TKI therapy discontinuation. We aimed to define precise conditions for stopping treatment.
Methods
In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. The primary endpoint was molecular relapse-free survival, defined by loss of major molecular response (MMR; >0·1% BCR-ABL1 on the International Scale) and assessed in all patients with at least one molecular result. Secondary endpoints were …
学术搜索中的文章
S Saussele, J Richter, J Guilhot, FX Gruber… - The Lancet Oncology, 2018